Adipose tissue-derived stem cells for veterinary use
An adipose tissue and stem cell technology, which can be used in drug combinations, medical raw materials derived from mammals, medical preparations containing active ingredients, etc., and can solve problems such as taking too long
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0079] The preparation of cell or tissue based therapeutic compositions is well known in the art. The composition can be formulated in a pharmaceutically acceptable medium. Cells can be in solution or embedded in a matrix. The preparation of therapeutic compositions having bioactive agents (eg, growth factors) as active ingredients is well known in the art. The active therapeutic ingredient is usually mixed with an excipient or vehicle which is pharmaceutically acceptable and compatible with the active ingredient. In addition, the composition, if desired, can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, which enhance the effectiveness of the active ingredients.
[0080] Bioactive agents can be formulated into therapeutic compositions in the form of neutralized pharmaceutically acceptable salts. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of peptide or antibody mole...
example 1
[0147] Example 1 Experimental Treatment of Canine Urinary Incontinence Using Adipose Tissue-Derived Stem Cells
[0148] Materials and methods
[0149] animal selection
[0150] Female dogs with overt UI symptoms were selected for this study. These symptoms include dribbling, loss of voluntary control, and / or urine burn dermatitis. To ensure that an individual's UI symptoms are due to a urethral defect, they must demonstrate responsiveness to PPA treatment. Each owner also agrees to enter this experimental study by signing a consent form stating that (1) the dog will undergo a test injection of ADSC in the hind leg to ensure that there is no immune response, (2) the PPA treatment of the dog will be Withdrawal for a number of days (up to 1 week) to allow UI symptoms to reappear, (3) dog must demonstrate reappearance of UI symptoms at least 3 days before undergoing ADSC treatment, and (4) if owner does not wish to reappear after PPA is withdrawn and / or Or caring for a dog a...
example 2
[0158] Example 2 Using ADSCs to Treat Osteoarthritis
[0159] treatment procedure
[0160] Although OA can afflict virtually any joint, it is most commonly associated with the knees and hips of the hind limbs. Injecting ADSCs into the joint is similar to injecting corticosteroids, except that a cell suspension is used instead of steroids. The volume of the cell suspension and the number of cells vary proportionally with the size of the individual. As an example, a 20kg dog will receive five million ADSCs per joint in 0.5ml PBS. After treatment, the owner is advised to walk the dog on a leash for 30 minutes a day. Dogs were allowed to continue taking any oral medications taken prior to ADSC treatment. Any intra-articular therapy prior to ADSC treatment should be discontinued.
[0161] Post-Treatment Evaluation
[0162] Animal evaluation will include medical records, physical examination, and lameness examination including joint mobility and pain documentation during man...
PUM
Login to view more Abstract
Description
Claims
Application Information
Login to view more - R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap